eATP and autoimmune diabetes

Area of Science:

• Immunology
• Endocrinology
• Pharmacology

Background:

• Extracellular ATP (eATP) is released during cell damage and activates purinergic receptors, influencing T lymphocyte function.
• T lymphocytes are key players in type 1 diabetes (T1D) pathogenesis and allograft rejection.
• This review focuses on ATP-mediated signaling in the immunological aspects of T1D.

Approach:

• Review of preclinical and clinical studies on purinergic signaling in T1D and transplantation.
• Analysis of therapeutic strategies targeting purinergic receptors.
• Evaluation of eATP-signaling inhibition for immune tolerance.

Key Points:

• eATP signaling is implicated in the early stages of T1D and allograft rejection.
• Drugs targeting purinergic signaling can modulate T lymphocyte activation and differentiation.
• Inhibition of eATP signaling has shown promise in inducing immune tolerance.

Conclusions:

• The purinergic system presents a novel therapeutic target for autoimmune diseases like T1D.
• Targeting eATP-mediated signaling could prevent or reverse T1D and improve islet transplant outcomes.
• eATP inhibition offers a potential strategy for managing auto- and allo-immunity.